Pancreatic Cancer Research

ResearcherJichi Medical UniversityNo recent work listed

Shoji Nakamori

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5014204252, A5110070274, A5111852416. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
138
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 4 papers · 2018: 5 papers · 2019: 2 papers · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper

Papers 31

  1. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  2. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  3. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  4. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  5. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. First author DOI 10.1002/cam4.3558↗
  6. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the … Co-author DOI 10.1097/mpa.0000000000001692↗
  7. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  8. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  9. [A Case of Long-Term Survival after Total Pancreatectomy for Recurrent Pancreatic Cancer in the Remnant Pancreas after Pancreatoduodenectomy]. Last author PMID 30914550↗
  10. Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemothe… Last author DOI 10.1007/s13691-017-0311-0↗
  11. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
  12. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. Last author DOI 10.1016/j.hbpd.2018.01.004↗
  13. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surge… Co-author DOI 10.1016/j.surg.2018.05.050↗
  14. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  15. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  16. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  17. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Co-author DOI 10.1016/j.cca.2017.02.011↗
  18. Prognostic impact of nodal statuses in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2017.01.003↗
  19. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Last author DOI 10.1016/j.pan.2015.10.006↗
  20. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Co-author DOI 10.1016/s0140-6736(16)30583-9↗
  21. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  22. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-B… Co-author DOI 10.1371/journal.pone.0161009↗
  23. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  24. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Co-author DOI 10.1038/srep15921↗
  25. Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1159/000439545↗
  26. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. First author DOI 10.1093/jjco/hyu143↗
  27. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. Co-author DOI 10.1371/journal.pone.0046908↗
  28. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyr090↗
  29. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2010.01810.x↗
  30. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-10-0397↗
  31. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer]. Co-author PMID 21566438↗

Closest collaborators

The 25 strongest of 138 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akira Fukutomi · 11 shared papers, 2015–2022 · strength 0.84
  2. Takuji Okusaka · 15 shared papers, 2011–2021 · strength 0.80
  3. Tatsuya Ioka · 13 shared papers, 2011–2021 · strength 0.74
  4. Naohiro Sata · 11 shared papers, 2011–2022 · strength 0.68
  5. Junji Furuse · 9 shared papers, 2011–2021 · strength 0.60
  6. Narikazu Boku · 10 shared papers, 2011–2022 · strength 0.58
  7. Atsushi Miyamoto · 7 shared papers, 2015–2021 · strength 0.52
  8. Soichiro Morinaga · 6 shared papers, 2016–2022 · strength 0.50
  9. Nobumasa Mizuno · 6 shared papers, 2016–2021 · strength 0.47
  10. Makoto Ueno · 5 shared papers, 2019–2021 · strength 0.46
  11. Masafumi Ikeda · 6 shared papers, 2015–2021 · strength 0.44
  12. Hiroshi Ishii · 5 shared papers, 2015–2021 · strength 0.38
  13. Katsuhiko Uesaka · 4 shared papers, 2016–2022 · strength 0.30
  14. Yukiyasu Okamura · 4 shared papers, 2016–2022 · strength 0.30
  15. Mitsugu Sekimoto · 4 shared papers, 2016–2019 · strength 0.30
  16. Hideki Ueno · 4 shared papers, 2017–2021 · strength 0.28
  17. Tadafumi Asaoka · 4 shared papers, 2015–2018 · strength 0.26
  18. Akiko Todaka · 3 shared papers, 2018–2021 · strength 0.25
  19. Masato Ozaka · 3 shared papers, 2018–2021 · strength 0.24
  20. Motohiro Hirao · 3 shared papers, 2016–2019 · strength 0.21
  21. Taketo Yamaguchi · 3 shared papers, 2017–2021 · strength 0.21
  22. Yasuo Ohashi · 4 shared papers, 2016–2018 · strength 0.21
  23. Masayuki Furukawa · 3 shared papers, 2016–2020 · strength 0.20
  24. Amane Takahashi · 2 shared papers, 2020–2022 · strength 0.20
  25. Hirochika Toyama · 2 shared papers, 2020–2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.